Healthcare · diabetes and obesity treatment

Novo Nordisk

NVODividend

Strong demand for diabetes and obesity treatment and the Wegovy pill rollout support recovery. For shareholders, the key is whether volumes outweigh pricing pressure and earnings turn into cash after investment.

Analysis and ratings: ChatGPT·Business analysis 11/9/2026·Ratings & valuation 11/9/2026
THESIS STATUSVolume recovery · continuing pricing pressure
CONFIDENCEMediumScale and profitability are documented; the business turnaround, pricing and success of the new offering are still being established.
HORIZON3 years and longer
WHAT MATTERS MOSTEarnings and cash growth per share after pricing changes and investment.

Business strength & price attractiveness

How AI assesses them

Business strength

Medium confidence
7.9/ 10

First recorded assessment ·

Business strength, independent of the stock price.

Demonstrated scale, manufacturing and research capabilities, and long-term demand. Financial strength is balanced against less predictable execution, portfolio concentration and weaker pricing power.

Five areas & supporting evidence

Price Attractiveness

Medium confidence
7/ 10

First recorded assessment ·

At 40.31 USD · close
Three-year horizon, through .

The base case offers +76.7% over three years, the bear case −18.5%, including dividends. The cash flow check shows a smaller safety margin than P/E; returns also depend on rerating to 15× earnings.

Scenarios & supporting evidence

What changed in the latest update

New information: Published a new analysis of Novo Nordisk (NVO).

Strength 7.9Attractiveness 7.0First recorded assessment
View rating history →

Assessed · Methodology 1.2. Analytical judgments by ChatGPT; price changes do not automatically update these scores.

MARKET OVERVIEW

NVO · Price chart

Delayed data · English controls.TradingView
Analysis contents · 13 sections
01

Company Snapshot

Independent ChatGPT assessment · November 9, 2026 · methodology 1.2

Novo Nordisk remains a strong pharmaceutical company with long-term demand for diabetes and obesity treatment. Q3 2026 results show a recovery in volumes and a successful launch of the Wegovy pill. For shareholders, however, the key questions are whether patient growth can outweigh falling net prices and whether high accounting earnings turn into cash after investment. The shares offer interesting potential, but currently require acceptance of business turnaround risk.

MetricPosition at the analysis date
CompanyNovo Nordisk A/S, Denmark
Assessed instrumentNVO, NYSE ADR, USD; 1 ADR represents 1 class B share
Domestic sharesNOVO B, Nasdaq Copenhagen, DKK
Reference quote40.31 USD, closing price on November 6, 2026, not a live November 9 quote
Latest resultsQ3 and first nine months of 2026, released November 4, 2026
Business strength7.9/10, medium confidence
Price attractiveness7.0/10 at 40.31 USD, medium confidence
Estimated current intrinsic value42–54 USD per ADR, working midpoint approximately 48 USD
Three-year horizonThrough November 2029; annual 2029 earnings serve as the valuation metric

Quote: Quiver Quantitative, corroborated by Financial Times. ADR ratio: company information. Methodology: Assessment methodology.

02

Investment Thesis

Analytical conclusion: long-term demand is very strong, but available reimbursement and competition limit the manufacturer's revenue opportunity. Novo can grow despite a lower market share if the overall treated market expands. Market growth alone does not guarantee earnings-per-share growth.

Eli Lilly remains the largest direct competitor. Efficacy, tolerability, ease of administration, price and reimbursement leave room for several products; leadership in a single study need not determine the commercial winner.

03

The Business

Novo develops, manufactures and sells medicines. Patients create demand, physicians decide on prescriptions, and access is influenced by insurers, employers, government programs and self-pay channels. The size of the population with obesity therefore cannot be translated directly into paying patient numbers.

AreaMain offeringEconomic significance
ObesityInjectable, high-dose and oral WegovyMain current growth engine
DiabetesOzempic, oral offering building on Rybelsus, insulinsLarge established base, alongside competitive and pricing pressure
Blood and endocrine disordersFor example Sogroya and Norditropin; upcoming denecimigSmaller base and diversification opportunity
Drug developmentCagriSema, zenagamtide, amylin and other moleculesFuture product renewal and protection against loss of exclusivity

The business model rests on long-term recurring treatment. This is not a contractually guaranteed subscription: patients can discontinue treatment, switch products or lose reimbursement. The product and development overview is based on the Q3 2026 call.

Cooperation with Hims and Hers

On March 9, 2026, Novo announced an agreement with Hims & Hers to offer approved Ozempic and Wegovy products, including the pill, at Novo self-pay prices. The agreement included changes to the promotion of compounded GLP-1 products and the option for existing patients to transition to approved medicines where clinically appropriate. Novo announcement

News on November 6, 2026: Eli Lilly also announced an agreement with HIMS providing access to Zepbound and Foundayu. HIMS is therefore developing as a distribution platform for multiple manufacturers. Lilly announcement

Analytical conclusion: for Novo this is useful patient access and broader distribution. It is not exclusive protection against Lilly. The published agreements do not allow a reliable estimate of incremental earnings for Novo; the model therefore adds no separate amount solely for HIMS.

04

Competitive Advantages

Business strength

Business strength: 7.9/10. Assessed on: November 9, 2026. Methodology: 1.2.

AreaScoreMain evidence
Competitive advantage7.6/10Established brands, manufacturing, distribution and a 54% GLP-1 volume share in IO according to the Q3 call; price erosion and loss of exclusivity show the limits of the advantage.
Demand durability9.0/10Chronic conditions and approximately 48 million people on treatment; obesity treatment base growing to 5.6 million according to the Q3 call. Reimbursement constrains realized demand.
Management execution6.2/10Return to growth and expansion of the oral offering; balanced against restructuring, manufacturing and development asset impairments, and the need to restore predictability.
Business economics8.2/10Q3 adjusted operating margin approximately 40% and full-year FCF outlook of 60–70 billion DKK; pricing pressure and investment limit earnings-to-cash conversion.
Financial resilience8.5/10Net debt excluding leases of 79.7 billion DKK at September 30, 2026, below the end of 2025; significant internal cash generation.

Calculation: (7.6 + 9.0 + 6.2 + 8.2 + 8.5) / 5 = 7.9. Each area has a 20% weight. Sources: call, Q3 presentation, slide 13 and report, appendix 7.

  • Brief rationale: Novo has demonstrated scale, manufacturing and research capabilities, and products addressing substantial medical needs. Financial strength supports continued development through a difficult period. Less predictable execution and weaker pricing power constrain the score.
  • Main weakness: value concentrated in related metabolic products and the ability to offset falling net prices through volume growth.
  • Assessment confidence: medium; scale and profitability are documented, but the business turnaround and success of the new offering are still being established.
  • Condition for change: an increase after several quarters of sustainable earnings and cash growth per share; a decrease with continued loss of competitive position, lasting margin deterioration or unsuccessful portfolio renewal.
05

Growth Drivers

Product or programWhat was announced on the Q3 callInvestment significance and limitations
Wegovy pillAround 80% of new US prescriptions within the oral segment according to management; expansion to more than 20 markets in H1 2027Broadens access and the patient pool; the quoted share is not a share of all GLP-1 products.
Wegovy HD 7.2 mgApproximately 80% of US high-dose prescriptions come from titration from 2.4 mgHelps retain patients; mostly not new customers.
CagriSemaPreparing for an early 2027 US launch, subject to approvalPotential growth renewal; approval and commercial uptake are not completed outcomes.
ZenagamtideOral AMAZE 9 in phase III, data expected in 2028Next generation combining GLP-1 and amylin biology.
Amylin and triple agonistsFurther data expected during 2027Long-term growth possibility with substantial clinical risk.
Denecimig and liver programsPreparing an expanded offering in hemophilia and MASHDiversification; no assumption of immediately replacing semaglutide's scale.

Source: earnings call. Timelines reflect management expectations as of November 4, 2026.

REIMAGINE 5 compared CagriSema 1.0/1.0 mg with tirzepatide 5 mg. Reported weight loss of 12.4% versus 9.1% cannot be generalized into superiority over all tirzepatide doses. Likewise, post-hoc findings in subgroups of women do not replace a prespecified direct comparison. Source T

Analytical conclusion: the base case requires success in part of the portfolio and normal commercial execution. It does not require every new molecule to win or a return to former GLP-1 growth rates.

AI as a research and operating tool

Novo announced partnerships with OpenAI on April 14, 2026, AWS on August 10, 2026 and Anthropic on September 16, 2026. The aims include processing scientific data, identifying drug candidates, supporting research workflows and improving operating efficiency. AWS also mentions a joint development center in London. OpenAI · AWS · Anthropic

Analytical conclusion: the company has data, scientists, clinical and manufacturing capabilities on which it can build AI benefits. Partnerships alone do not demonstrate a higher probability of drug approval. No separate AI premium is added to valuation; any benefit must appear in development productivity, successful products or costs. AI also helps competitors.

06

Economics & Financial Profile

Amounts are in billions of DKK, except EPS. CER means constant exchange rates.

MetricQ3 20269M 2026
Adjusted sales79.2227.7
Year-over-year adjusted sales growth at CER+4%+2%
Adjusted operating profit31.798.0
Adjusted operating margin40.1%43.0%
Reported net profit16.786.3
Adjusted diluted EPS in DKK5.7918.60
Free cash flow under the company definition28.583.8

Sources: presentation, slide 13 and report, financial overview and appendix 7.

The 27% growth in adjusted operating profit at CER is not the company's new growth rate. It benefited substantially from the comparison with transformation costs in Q3 2025. Full-year adjusted sales and operating profit guidance remains between −2% and +2% at CER. Source T

Reported 9M results were affected by the release of a 26.8 billion DKK 340B provision; this is not recurring medicine sales. Q3 adjusted EPS fell 12% year over year. Adjusted operating profit and adjusted EPS also use different adjustment definitions. Source S

Analytical conclusion: valuation cannot mechanically annualize reported 9M earnings or treat adjusted EBIT growth as EPS growth. Sustainable earnings after pricing changes matter.

The company expects 2026 FCF of 60–70 billion DKK. Investment is expected to decline gradually; CAPEX guidance is approximately 50 billion DKK. 9M FCF cannot be extrapolated linearly to the full year because payment timing affects it. Sources T and V

Net debt excluding leases was 79.7 billion DKK at the end of September versus 95.4 billion DKK at the end of 2025. Source S Financial risk therefore currently centers mainly on returns on investment and development, and less on the need to raise external capital.

07

Key KPIs

Management reported approximately 48 million people receiving diabetes and obesity treatment, including 5.6 million receiving obesity treatment. According to the company, Novo has a 54% GLP-1 volume share in International Operations. These figures demonstrate scale; they do not represent global value share of the entire obesity market. Source T

The change in direction is positive: adjusted sales at constant exchange rates fell 2% year over year in Q4 2025 and 4% in Q1 2026, before growing 7% in Q2 and 4% in Q3 2026. The company added approximately 2.5 million people on treatment across Q2 and Q3 combined. Source T

08

Management & Capital Allocation

CEO Mike Doustdar described an ambition for mid-single-digit annual sales growth over 2026–2030. This is a strategic ambition, not confirmed guidance for every year. Luigi La Corte is to succeed Karsten Knudsen as CFO; Knudsen is to remain until year-end for the handover. Source T

The announced 2026 interim dividend was 3.75 DKK per share. This is not the full-year dividend. Future dividends in the model below are analytical estimates. Source D

09

Risks / Bear Case

RiskHow it damages shareholder valueWhat to monitor
Falling net pricesMore patients may not ensure revenue or earnings growthNet prices, reimbursement mix and margins
Competition from Lilly and othersPatient switching, lower prices, higher marketing costsShares in comparable segments and commercial uptake of new drugs
Reimbursement and the Bridge programSome growth may depend on access to temporarily supported treatmentVolume outside Bridge and continued reimbursement after 2027
Loss of exclusivityGeneric competition reduces prices and returns on established productsCanada, China and other individual jurisdictions
Development failureLoss of invested capital and future portfolio renewalRegulatory decisions, full clinical data and discontinued programs
Excess or unsuitable manufacturing capacityImpairments and weaker cash flow amid high investmentCAPEX, factory utilization and earnings-to-cash conversion
Currency movementsImpact on DKK results and the USD value of ADRsUSD/DKK, hedging and sales mix

On the call, management discussed longer-term Ozempic price erosion of approximately 10–15% annually and a Wegovy decline of around 30–35% in that quarter. This is not uniform price guidance for the whole company. It also said that a substantial part of sequential US pill growth relates to Bridge, and that the category excluding its contribution was relatively flat from May to October. Source T

10

Valuation

ChatGPT produces the calculations and valuation scenarios. Share-price inputs are dated to the analysis; they are not continuously updated market data.

CHATGPT SCENARIOS · November 2029 · terminal prices excluding dividends

Different outcomes. Different values.

Historical analysis input
40.31 USD · November 6, 2026
Bear
28.7 USD
Base
65.8 USD
Conditional scenarios from the analysis. The dashed line marks the historical share price used in the calculation. Values are neither current intrinsic value nor a share-price forecast.

Price Attractiveness

Price Attractiveness: 7.0/10 at 40.31 USD, quote dated November 6, 2026, assessed November 9, 2026. Horizon: three years. Methodology: 1.2.

Shared assumptions

All forecasts below are ChatGPT's own assumptions, not company guidance or market consensus.

  • Starting normalized 2026 EPS: 24.0 DKK. It builds on adjusted 9M EPS of 18.60 DKK and assumes a further 5.40 DKK in Q4; it must not be presented as a reported full-year figure. Reported base
  • Approximately 4.42 billion shares, including all classes, based on the Q3 diluted average. The count is held constant in every scenario: no additional buyback benefit or significant net dilution.
  • A technical exchange rate of 6.70 DKK per USD in every scenario; this is a fixed analytical assumption, not a verified current currency quote.
  • EPS includes financing costs and taxes. Debt is therefore not deducted again under the P/E method. Dividends exclude reinvestment and are before taxes, fees and USD/CZK changes.
  • Under this normalization, the starting price represents approximately 11.3 times EPS. A low P/E alone does not imply the same cheapness on a cash basis.

Comparable scenarios through November 2029

ItemBase caseBear caseBull case
Business assumptionsSales grow around 5% annually, new products offset pricing; operating margin around 40–42%Price erosion, loss of exclusivity and weaker reimbursement; sales stagnate or decline slightly, margin around 33–35%Faster treatment expansion and success of several products; sales approximately +9% annually, margin around 42–44%
Normalized 2029 EPS29.40 DKK, approximately 7% annual growth19.20 DKK, 20% below the starting base33.70 DKK, approximately 12% annual growth
Future P/E15×10×18×
Price in three years65.82 USD28.66 USD90.54 USD
Dividends over three years5.40 USD4.20 USD6.00 USD
Total three-year return from 40.31 USD+76.7%−18.5%+139.5%
Annualized equivalent of total return+20.9%−6.6%+33.8%

Price = EPS in DKK × P/E / 6.70. Total return = (price in three years + dividends) / 40.31 − 1. For simplicity, annualization assumes all dividends at the horizon end; it is not the exact internal rate of return on interim payments.

The base multiple of 15× reflects a strong, profitable pharmaceutical company with modest growth, without its former growth premium. The bear multiple of 10× values a permanently weakened position and the risk of further decline. The bull multiple of 18× requires successful growth renewal.

A substantial part of the base return comes from rerating from approximately 11× to 15× earnings. At an unchanged low multiple, the return would be materially lower. The bear case is not the worst possible outcome; serious safety or regulatory problems could cause a larger loss.

Current intrinsic value and cash flow check

Discounting the base target price and three annual dividends of 1.80 USD at a required return of 10% gives 53.9 USD today. This valuation is based on earnings and a future multiple, not an operating cash flow DCF.

A separate indicative DCF uses FCFF, cash after taxes and investment before financing, of 75 / 82 / 90 / 98 / 105 billion DKK in 2027–2031, terminal growth of 2.5%, 4.42 billion shares and the exchange rate above. This is a separate normalized forecast, not a mechanical adoption of the company's FCF metric. It assumes a gradual decline in investment intensity; operating lease payments are included in the forecast.

WACCEnterprise valueADR value after deducting net debt of 79.7 billion DKK
8.5%1,543 billion DKK49.4 USD
9.5%1,317 billion DKK41.8 USD
10.5%1,148 billion DKK36.1 USD

Net debt is deducted only in this enterprise DCF; lease debt is not included a second time. Terminal value represents approximately 74% of enterprise value at a WACC of 9.5%, making the result sensitive to long-term competitiveness.

The working current IV range is 42–54 USD, supported by the central DCF and discounted base case. It is not the range of all possible outcomes; DCF sensitivity extends lower. At 40.31 USD, the discount to the working midpoint of 48 USD is approximately 16%.

Expectations check: with hypothetical starting normalized FCFF of 65 billion DKK, a WACC of 9.5% and terminal growth of 2.5%, a price of 40.31 USD corresponds to approximately 9.4% annual FCFF growth for five years. The market may therefore price in some cash flow recovery even though P/E looks very low.

  • Brief rationale: the base case offers a substantial three-year return without requiring exceptional growth. A more cautious cash flow check, however, shows a smaller safety margin than P/E suggests. This corresponds to the lower end of attractive valuation, rather than an exceptional opportunity.
  • Main weakness: recovery of cash after investment and the assumed return to 15× earnings.
  • Assessment confidence: medium; the quote and starting results are documented, but prices, reimbursement and commercial success of new medicines have a substantial range of outcomes.
  • Condition for change: higher attractiveness following a price decline without business deterioration or confirmation of stronger FCF; lower above 55 USD without higher estimates or if normalized earnings power declines.
11

What Would Change the Assessment?

What would confirm the thesis: obesity treatment growth outside Bridge, a successful CagriSema launch, maintained margins, falling CAPEX with manufacturing reliability preserved, and higher cash per share.

What would undermine the thesis: several quarters of falling normalized EPS despite patient growth, further significant manufacturing investment impairments, lasting reimbursement deterioration or failure of new products to replace price and patent erosion.

12

Current View

The bands are analytical conditions for monitoring the shares, derived from current assumptions.

NVO ADR bandMeaningNecessary condition
36–40 USDFirst band for gradual entryMaintained guidance and evidence that higher volumes offset pricing
30–34 USDGreater safety marginPrice decline without structural damage to key products
42–54 USDWorking current IV rangeFurther decisions based on execution and cash generation
Above 55 USDSmaller margin under today's modelRequires better results or lower risk
13

Thesis History / Updates

DateMethodologyBusiness strengthPrice attractivenessQuoteReason
November 9, 20261.27.9/107.0/1040.31 USD, November 6, 2026 closeFirst analysis after Q3; volume recovery, continuing pricing pressure and valuation checked against cash flow.

Main sources for both scores:

The analysis is ChatGPT's independent judgment. Intrinsic value estimates and scenarios express assumptions, not certainty of future returns.

Was this analysis useful to you?

Have a suggestion about this analysis?

Suggestions are not displayed publicly. They help inform future updates. No name or email is required.

Sources and scenarios reflect the date stated in the analysis.Back to all companies